On Wednesday, OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI)’s shares declined -14.38% to $2.50.
OncoGenex Pharmaceuticals, Inc. (OGXI) declared initial results from the Phase 2 Rainier™ study evaluating apatorsen in combination with ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine contrast to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer. The addition of apatorsen to ABRAXANE and gemcitabine did not demonstrate a survival benefit contrast to ABRAXANE and gemcitabine alone. The study was sponsored and conducted by Sarah Cannon Research Institute (SCRI) and further results will be presented by SCRI at a future medical meeting.
Pancreatic cancer accounts for about 338,000 new cases each year worldwide. In the U.S., it continues to be the fourth leading cause of cancer death. Most pancreatic cancer patients will die within the first year of diagnosis, and five-year survival rates are less than 10 percent.
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company’s product candidates comprise Custirsen that is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, in addition to in patients with non-small cell lung cancer; and Apatorsen, which is in two Phase I and seven randomized Phase II trials for the treatment of bladder, lung, pancreatic, and prostate cancers.
HSBC Holdings plc (ADR) (NYSE:HSBC)’s shares gained 0.48% to $37.97.
According to a recent HSBC survey, sixty-five percent of parents in the U.S. would consider sending their child abroad for all or part of their university education, with Japan and China seen as offering the highest quality education accessible outside the U.S.
The HSBC Value of Education report Learning for Life shows that among 16 countries surveyed, parents in 12 countries consider the U.S. to be the international destination offering the highest quality education. Only in the United States did parents identify China as one of the countries offering the best education abroad. Among U.S. parents, 42% ranked an American education within the top three accessible worldwide (contrast to 51% of parents globally), while 39% ranked China in the top three (contrast to 13% globally).
When it comes to study abroad, 41 percent of U.S. parents would consider sending their children abroad for a semester or partial course of study at either undergraduate or postgraduate level, while 36 percent would consider full-time enrollment in an international college. Globally, an average of 44 percent and 53 percent of parents respectively would consider these types of international opportunities.
HSBC Holdings plc provides banking and financial products and services. It operates through four businesses Retail Banking and Wealth Administration, Commercial Banking, Global Banking and Markets, and Global Private Banking.
At the end of Wednesday’s trade, SolarCity Corp (NASDAQ:SCTY)‘s shares dipped -7.72% to $43.78.
The Northern and Central California SunShot Alliance declared plans to construct and interconnect rooftop solar systems in one day or less, an unprecedented aim given the industry’s current average of 30 days. In a contest sponsored by the U.S. Department of Energy SunShot Initiative, teams made up of local governments, solar and technology companies, and electric utilities will compete for a total of $10 million in cash prizes that will go back into local communities.
The alliance, which comprises Pacific Gas and Electric Company, SolarCity, Qado Energy, Accela and the City of Livermore, will compete in the small systems category (1 - 100 kW) for a first-place prize of $3 million and second-place prize of $1 million. The potential winnings would be split between the City of Livermore and possibly other jurisdictions that will use the funds to enhance the solar experience in their communities. The alliance is also eligible for the Change Prize Award of $100,000, which will be used to develop necessary technologies and recruit additional jurisdictions to join the team.
SolarCity Corporation designs, manufactures, installs, maintains, monitors, leases, and sells solar energy systems to residential, commercial, government, and other customers in the United States.
Sanofi SA (ADR) (NYSE:SNY), ended its Wednesday’s trading session with 0.66% gain, and closed at $48.15.
Genzyme, a Sanofi company, declared recently that new investigational data on its marketed treatments, Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab), in addition to data from the company’s MS pipeline, will be presented during the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The meeting, to be held in Barcelona, Spain, October 7-10th, will feature more than 50 platform and poster presentations of investigational data from across Genzyme’s MS franchise.
In addition to its marketed therapies, Genzyme has an MS R&D pipeline seeking to address unmet needs for relapsing and progressive forms of MS through research in selective immunomodulation, neuroprotection and remyelination.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
